Antidepressant selection and use and healthcare expenditures. An empirical approach

PharmacoEconomics

Volumn 13, Issue 4, 1998, Pages 435-448

  Crown, William H ^a   Hylan, Timothy R ^b,c   Meneades, Laurie ^a  

^a MEDSTAT GROUP   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ARTICLE; CONTROLLED STUDY; DATA BASE; DEPRESSION; DISEASE SEVERITY; DRUG PREFERENCE; DRUG USE; FEMALE; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; PHARMACOECONOMICS; POPULATION; PRESCRIPTION; PRIORITY JOURNAL; SAMPLING; UNITED STATES;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; HEALTH EXPENDITURES; HUMANS;

EID: 0031912692     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199813040-00006     Document Type: Article

References (33)

1. Simon GE, Von Korff M, Heiligenstein JH, et al. Initial antidepressant choice in primary care: effectiveness and cost of fluoxetine vs. tricyclic antidepressants. JAMA 1996; 275 (24): 1897-902
2. Heckman JJ, Smith JA. Assessing the case for social experiments. J Econ Perspect 1995; 9 (2): 85-110
3. Simon GE, Fishman P. Cost implications of initial antidepressant selection in primary care. Pharmacoeconomics 1998; 13 (1 Pt 1): 61-70
4. Croghan TW, Lair TJ, Engelhart L, et al. Effect of antidepressant therapy on health care utilization and costs in primary care. Psychiatr Serv 1997; 48 (11): 1420-6
5. Hylan TR, Crown WH, Meneades L, et al. TCA and SSRI antidepressant selection and health care costs in the naturalistic setting: a multivariate analysis. J Affect Disord 1998; 47: 71-9
6. Sheldon TA. Problems of using modelling in the economic evaluation of health care. Health Econ 1996; 5: 1-11
7. Sturm R, Wells K. How can care for depression become more cost-effective? JAMA 1995; 273 (1): 51-8
8. Mintz J, Mintz LI, Arruda MJ, et. al. Treatments of depression and the functional capacity to work. Arch Gen Psychiatry 1992; 49 (10): 761-8
9. Agency for Health Care Policy Research (AHCPR). Treatment of major depression: clinical practice guidelines no. 5, vol. 2. Rockville (MD): US Department of Health and Human Services, 1993. AHCPR publication no.: 93-0550
10. Katon W, Von Korff M, Lin E, et al. Adequacy and duration of antidepressant treatment in primary care. Med Care 1992; 30 (1): 67-76
11. Simon G, Von Korff M, Wagner EH, et. al. Patterns of antidepressant use in community practice. Gen Hosp Psychiatry 1993; 15 (6): 399-408
12. Johnson D. Noncompliance with antidepressant therapy: an underestimated problem. Intern Med 1986; 11: 14-7
13. Lin EH, Von Korff M, Katon W, et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care 1995; 33 (1): 67-74
14. Thompson D, Buesching D, Gregor K, et al. Patterns of antidepressant use and their relation to costs of care. Am J Manage Care 1996; 2 (9): 1239-46
15. Murnane R, Newstead S, Olsen R. Comparing public and private schools: the puzzling role of selectivity bias. J Econ Bus Stat 1985; 3 (1): 23-35
16. Heckman J. The common structure of statistical models of truncation, sample selection and limited dependent variables and a simple estimator for such models. Ann Econ Soc Meas 1976; 5: 475-92
17. Heckman J. Sample selection as a specification error. Econometrica 1979; 47 (1): 153-61
18. Maddala GS. Introduction to econometrics. New York: Macmillan Publishing Co., 1988
19. Greene WH, Limdep [computer program]. Vol. 7, New York: Econometric Software; 1995
20. Obenchain RL, Melfi CA, Croghan TW, et al. Bootstrap analyses of cost-effectiveness in antidepressant pharmacotherapy. Pharmacoeconomics 1997; 11 (5): 464-72
21. Maddala GS. Limited and dependent and qualitative variables in econometrics. Cambridge: Cambridge University Press, 1983
22. Maddala GS, Lee LF. Recursive models with qualitative endogenous variables. Ann Econ Soc Meas 1976; 5 (4): 525-45
23. Greene WH. Econometric analysis. New York: MacMillan Publishing Company, 1993
24. Skaer TL, Sclar DA, Robison L, et al. Economic valuation of amitriptyline, desipramine, nortriptyline, and sertraline in the management of patients with depression. Curr Ther Res 1995; 56 (6): 556-67
25. Sclar DA, Robison LM, Skaer TL, et. al. Antidepressant pharmacotherapy: economic outcomes in a health maintenance organization. Clin Ther 1994; 16 (4): 715-30
26. Sclar DA, Robison LM, Skaer T, et al. Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine, and sertraline in a health maintenance organization. J Int Med Res 1995; 23: 395-412
27. Henk H, Katzelnick DJ, Kobak KA, et al. Medical costs attributed to depression among patients with a history of high medical expenses in a health maintenance organization. Arch Gen Psychiatry 1996; 53 (10): 899-904
28. Simon GE, VonKorff M, Barlow W. Health care costs associated with depressive and anxiety disorders in primary care. Am J Psychiatry 1995; 152 (3): 352-7
29. Song F, Freemantle N, Sheldon TA, et. al. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ 1993; 306: 683-7
30. Woods S, Rizzo J. Cost-effectiveness of antidepressant treatment reassessed. Br J Psychiatry 1997; 170: 257-63
31. Simon GE, Von Korff M. Recognition, management and outcomes of depression in primary care. Arch Fam Med 1995; 4 (2): 99-105
32. Rost K, Smith GR, Matthews DB, et al. The deliberate misdiagnosis of major depression in primary care. Arch Fam Med 1994; 3: 333-7
33. Gregor K, Overhage JM, Coon SJ, et. al. Selective serotonin reuptake inhibitor dose titration in a naturalistic setting. Clin Ther 1994; 16 (2): 306-15